Download PDF
Semin Neurol 2014; 34(01): 007-013
DOI: 10.1055/s-0034-1372337
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Evolving Character of Chronic Central Nervous System HIV Infection

Richard W. Price
1   Department of Neurology, University of California, San Francisco, California
,
Serena S. Spudich
2   Department of Neurology, Yale University, New Haven, Connecticut
,
Julia Peterson
1   Department of Neurology, University of California, San Francisco, California
,
Sarah Joseph
3   UNC Center for AIDS Research and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
,
Dietmar Fuchs
4   Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
,
Henrik Zetterberg
5   Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden and Institute of Neurology, Queen Square, London, United Kingdom
,
Magnus Gisslén
6   Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
,
Ronald Swanstrom
3   UNC Center for AIDS Research and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2014 (online)

    Permissions and Reprints

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system (CNS) begins early in systemic infection and continues throughout its untreated course. Despite a common cerebrospinal fluid inflammatory response, it is usually neurologically asymptomatic for much of this course, but can evolve in some individuals to HIV-associated dementia (HAD), a severe encephalopathy with characteristic cognitive and motor dysfunction. While widespread use of combination antiretroviral therapy (ART) has led to a marked decline in both the CNS infection and its neurologic severe consequence, HAD continues to afflict individuals presenting with advanced systemic infection in the developed world and a larger number in resource-poor settings where ART is more restricted. Additionally, milder CNS injury and dysfunction have broader prevalence, including in those treated with ART. Here we review the history and evolving nomenclature of HAD, its viral pathogenesis, clinical presentation and diagnosis, and treatment.

Keywords

HIV - dementia - treatment - brain - inflammation - cerebrospinal fluid - biomarkers
 

  • References

  • 1 Davis LE, Hjelle BL, Miller VE , et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42 (9) 1736-1739
    CrossrefPubMedGoogle Scholar
  • 2 Spudich S, Gisslen M, Hagberg L , et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011; 204 (5) 753-760
    CrossrefPubMedGoogle Scholar
  • 3 Valcour V, Chalermchai T, Sailasuta N , et al; RV254/SEARCH 010 Study Group. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012; 206 (2) 275-282
    CrossrefPubMedGoogle Scholar
  • 4 Ellis RJ, Hsia K, Spector SA , et al; HIV Neurobehavioral Research Center Group. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997; 42 (5) 679-688
    CrossrefPubMedGoogle Scholar
  • 5 Spudich SS, Nilsson AC, Lollo ND , et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5: 98
    CrossrefPubMedGoogle Scholar
  • 6 Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239 (4840) 586-592
    CrossrefPubMedGoogle Scholar
  • 7 Price RW, Peterson J, Fuchs D , et al. Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol 2013; 8 (5) 1147-1158
    CrossrefPubMedGoogle Scholar
  • 8 Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39 (4) 633-645
    CrossrefPubMedGoogle Scholar
  • 9 Spudich S, González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2012; 2 (6) a007120
    PubMedGoogle Scholar
  • 10 Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev 2013; 254 (1) 102-113
    CrossrefPubMedGoogle Scholar
  • 11 Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19 (6) 517-524
    CrossrefPubMedGoogle Scholar
  • 12 Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9 (2) 139-147
    CrossrefPubMedGoogle Scholar
  • 13 El-Sadr WM, Lundgren J, Neaton JD , et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355 (22) 2283-2296
    CrossrefPubMedGoogle Scholar
  • 14 El-Sadr WM, Grund B, Neuhaus J , et al; SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149 (5) 289-299
    CrossrefPubMedGoogle Scholar
  • 15 Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22 (18) 2409-2418
    CrossrefPubMedGoogle Scholar
  • 16 Mellors JW, Muñoz A, Giorgi JV , et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126 (12) 946-954
    CrossrefPubMedGoogle Scholar
  • 17 Lyles RH, Tang AM, Smit E , et al. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999; 22 (4) 386-394
    CrossrefPubMedGoogle Scholar
  • 18 Giorgi JV, Lyles RH, Matud JL , et al; Multicenter AIDS Cohort Study. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29 (4) 346-355
    CrossrefPubMedGoogle Scholar
  • 19 Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010; 5 (6) 480-490
    CrossrefPubMedGoogle Scholar
  • 20 Shacklett BL, Cox CA, Wilkens DT , et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis 2004; 189 (12) 2202-2212
    CrossrefPubMedGoogle Scholar
  • 21 Sadagopal S, Lorey SL, Barnett L , et al. Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects. J Virol 2008; 82 (21) 10418-10428
    CrossrefPubMedGoogle Scholar
  • 22 Ho EL, Ronquillo R, Altmeppen H, Spudich SS, Price RW, Sinclair E. Cellular composition of cerebrospinal fluid in HIV-1 infected and uninfected subjects. PLoS ONE 2013; 8 (6) e66188
    CrossrefPubMedGoogle Scholar
  • 23 Hagberg L, Cinque P, Gisslen M , et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7: 15
    CrossrefPubMedGoogle Scholar
  • 24 Yilmaz A, Yiannoutsos CT, Fuchs D , et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 2013; 10: 62
    CrossrefPubMedGoogle Scholar
  • 25 Abdulle S, Mellgren A, Brew BJ , et al. CSF neurofilament protein (NFL)—a marker of active HIV-related neurodegeneration. J Neurol 2007; 254 (8) 1026-1032
    CrossrefPubMedGoogle Scholar
  • 26 Peluso MJ, Meyerhoff DJ, Price RW , et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013; 207 (11) 1703-1712
    CrossrefPubMedGoogle Scholar
  • 27 Antinori A, Arendt G, Becker JT , et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69 (18) 1789-1799
    CrossrefPubMedGoogle Scholar
  • 28 Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog 2009; 5 (4) e1000395
    CrossrefPubMedGoogle Scholar
  • 29 Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 2011; 7 (10) e1002286
    CrossrefPubMedGoogle Scholar
  • 30 Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep 2012; 9 (1) 52-63
    CrossrefPubMedGoogle Scholar
  • 31 González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5 (1) 69-81
    CrossrefPubMedGoogle Scholar
  • 32 Weiser B, Philpott S, Klimkait T , et al; Swiss HIV Cohort Study. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22 (4) 469-479
    CrossrefPubMedGoogle Scholar
  • 33 Spudich SS, Huang W, Nilsson AC , et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191 (6) 890-898
    CrossrefPubMedGoogle Scholar
  • 34 Staprans S, Marlowe N, Glidden D , et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999; 13 (9) 1051-1061
    CrossrefPubMedGoogle Scholar
  • 35 Ellis RJ, Gamst AC, Capparelli E , et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000; 54 (4) 927-936
    CrossrefPubMedGoogle Scholar
  • 36 Spudich S, Price RW. Neurologic disease. In: Dolin R, Masur H, Saag MS, , eds. AIDS therapy. 3rd ed. Philadelphia, PA: Churchill Livingston Elsevier; 2008: 1075-1101
    Google Scholar
  • 37 Brew BJ, Bhalla RB, Paul M , et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 1992; 6 (5) 461-465
    CrossrefPubMedGoogle Scholar
  • 38 Gisslén M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther 2005; 2: 6
    CrossrefPubMedGoogle Scholar
  • 39 Gisslen M, Hagberg L, Rosengren L , et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2007; 2 (1) 112-119
    CrossrefPubMedGoogle Scholar
  • 40 Letendre S, Marquie-Beck J, Capparelli E , et al; CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65 (1) 65-70
    CrossrefPubMedGoogle Scholar
  • 41 Yilmaz A, Price RW, Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 2012; 67 (2) 299-311
    CrossrefPubMedGoogle Scholar
  • 42 Dennis AM, Napravnik S, Seña AC, Eron JJ. Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis 2011; 53 (5) 480-487
    CrossrefPubMedGoogle Scholar
  • 43 Likatavicius G, Van de Laar M. HIV and AIDS in the European Union, 2011. Euro Surveill 2012; 17 (48) 20329
    PubMedGoogle Scholar
  • 44 Edén A, Fuchs D, Hagberg L , et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202 (12) 1819-1825
    CrossrefPubMedGoogle Scholar
  • 45 Canestri A, Lescure FX, Jaureguiberry S , et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50 (5) 773-778
    CrossrefPubMedGoogle Scholar
  • 46 Peluso MJ, Ferretti F, Peterson J , et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012; 26 (14) 1765-1774
    CrossrefPubMedGoogle Scholar
  • 47 Price RW, Epstein LG, Becker JT , et al. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007; 69 (18) 1781-1788
    CrossrefPubMedGoogle Scholar